Procter & Gamble: Strong Sales, Weak Earnings—Buy Now or Wait?

Procter & Gamble (PG) reported fiscal 2027 first-quarter results that initially excited investors, sending shares up more than 5%. The consumer staples giant posted organic sales growth of 4%, a significant improvement from the 1% growth in the prior quarter. This acceleration was driven primarily by volume (up 2.4%) and product mix (up 1.1%), rather than price increases (up only 0.4%). That's a healthy sign because it indicates consumers are buying more of P&G's products, not just paying higher prices.

The strongest volume growth came from fabric and home care (up 4.3%), followed by baby, feminine, and family care (up 2.3%) and beauty (up 2.2%). These gains offset declines in healthcare (down 2.9%) and grooming (down 0.4%). Management noted that innovation-based pricing and a more favorable premium product mix contributed to the top-line beat.

However, the bottom line was less impressive. Core adjusted earnings per share (EPS) rose just 1% to $2.00, a modest improvement from the 3% decline in the previous quarter but still far below the company's long-term target of mid-to-high single-digit growth. P&G is facing higher commodity costs and tariff-related headwinds that are squeezing margins.

Despite the strong start to the fiscal year, P&G reaffirmed its full-year organic sales growth guidance of 1% to 3%, suggesting management isn't yet convinced the recovery is sustainable. The company also maintained its adjusted EPS growth outlook of 0% to 3%, or $6.89 to $7.11 per share, citing an estimated $0.79 per share drag from higher commodity costs, interest expenses, and other headwinds—an 11% impact.

On the positive side, P&G continues to generate robust cash flow. In the first quarter alone, it produced $5.8 billion in operating cash flow and $4.4 billion in free cash flow, funding $2.6 billion in dividend payments and $1.3 billion in share repurchases. For the full year, the company expects to return more than $15 billion to shareholders.

The mixed earnings report raises a critical question for investors: is P&G's recovery gaining enough momentum to justify buying the stock after its recent rally? At around $165 per share and with full-year EPS expected at $7.00 (the midpoint), PG trades at roughly 23.5 times forward earnings. That's cheaper than its late-2024 peak of over 26x but richer than the sub-21x level seen earlier this year. The recent pop has also pushed the dividend yield down from about 3% to 2.7%.

P&G's premium valuation is supported by its portfolio of durable brands like Tide, Pampers, and Mr. Clean, as well as its resilient cash flows. However, to deliver a compelling total return from here, the company needs to accelerate earnings growth and potentially see its valuation multiple expand further. For example, generating a 10% annualized total return over the next five years would require EPS growth of 5% to 6% and a valuation multiple of 25x to 26x, including dividends. That's possible, but the margin of safety is thin after the post-earnings pop.

The key risk is that P&G fails to return to mid-single-digit EPS growth. If that happens, the stock could lose its valuation premium, leading to lackluster returns. Given the uncertain macro environment and persistent cost pressures, the company's turnaround is not yet proven.

For long-term investors, P&G remains a high-quality defensive dividend stock. But after the recent rally, the risk/reward is less attractive. It may be wise to wait for a more favorable entry point rather than chase the stock at current levels.